| Source: HalifaxProj(inhibit) |
| Type: |
| A family of enzymes that play a crucial role in the signaling pathways of various cytokines and growth factors. They are involved in the regulation of immune responses, hematopoiesis, and cell proliferation. Dysregulation of JAK signaling has been implicated in several types of cancer, particularly hematological malignancies such as leukemia and lymphoma. Targeting JAKs with specific inhibitors has emerged as a therapeutic strategy in oncology. JAK inhibitors, such as ruxolitinib and tofacitinib, are used to treat certain blood cancers and autoimmune diseases. These drugs work by blocking the activity of JAKs, thereby inhibiting the signaling pathways that promote cancer cell proliferation and survival. |
| Renal cell carcinoma (RCC) is one of the most common malignant tumors of the urinary system, accounting for 80–90% of kidney neoplasms. The activation of the mTOR pathway has been found in RCC and is correlated with high grade and poor prognostic patient features (41,42). |
| 3179- | Ash, | Withaferin A inhibits JAK/STAT3 signaling and induces apoptosis of human renal carcinoma Caki cells |
| - | in-vitro, | RCC, | Caki-1 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:24 Cells:% prod#:% Target#:162 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid